<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009646</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0011</org_study_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD021364</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>U10HD021397</secondary_id>
    <secondary_id>U10HD027881</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD021373</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>MT-13288</secondary_id>
    <secondary_id>M01RR000997</secondary_id>
    <secondary_id>M01RR000070</secondary_id>
    <nct_id>NCT00009646</nct_id>
  </id_info>
  <brief_title>Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)</brief_title>
  <acronym>TIPP</acronym>
  <official_title>Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was to determine whether giving low-dose indomethacin to infants weight 500 to 999
      grams (approximately 1 to 2 pounds) at birth improves their survival without cerebral palsy
      or developmental problems at 18 to 22 months of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prophylactic indomethacin reduces patent ductus arteriosus (PDA) and intraventricular
      hemorrhage in very low birth weight infants. However, the effects of early indomethacin on
      long-term neurodevelopment remain uncertain. There is also insufficient evidence to rule out
      serious adverse effects, such as increases in the risk of necrotizing enterocolitis (NEC) and
      retinopathy of prematurity (ROP). The aim of this trial was to determine if prophylactic
      administration of indomethacin improves survival without neurosensory impairments in
      extremely-low-birth-weight infants. Infants (n=1202) with birthweights 500 to 999 grams were
      randomized between 2 and 6 hours after birth to receive either intravenous indomethacin (0.1
      mg/kg) or equal volumes of normal saline placebo, daily for 3 days. The primary outcomes at a
      corrected age of 18 months was a composite of death, cerebral palsy, cognitive delay,
      deafness, or blindness. Secondary long-term outcomes were hydrocephalus necessitating the
      placement of a shunt, seizure disorder, and microcephaly. Secondary short-term outcomes were
      patent ductus arteriosus, pulmonary hemorrhage, chronic lung disease, cranial
      ultrasonographic abnormalities, nectrotizing enterocolitis and retinopathy. Infants were
      evaluated in follow-up at 18-22 months corrected age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1993</start_date>
  <completion_date type="Actual">March 2001</completion_date>
  <primary_completion_date type="Actual">March 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or Neurodevelopment Impairment</measure>
    <time_frame>18-22 Months Corrected Age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patent ductus arteriosus</measure>
    <time_frame>120 Days of Life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary Dysplasia (BPD)</measure>
    <time_frame>120 Days of Life</time_frame>
    <description>Chronic Lung Disease (CLD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis (NEC)</measure>
    <time_frame>120 Days of Life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial abnormalities</measure>
    <time_frame>120 Days of Life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity (ROP)</measure>
    <time_frame>18-22 Months Corrected Age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary hemorrhage</measure>
    <time_frame>120 Days of Life</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1202</enrollment>
  <condition>Infant, Very Low Birth Weight</condition>
  <condition>Infant, Premature</condition>
  <condition>Ductus Arteriosus, Patent</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indomethacin</intervention_name>
    <description>Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>0.1 mg per kilogram of body weight</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.1 mg per kilogram of body weight</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight 500 to 999 grams;

          -  Postnatal age greater than 2 hours;

        Exclusion Criteria:

          -  Unable to administer study drug within 6 hours of birth;

          -  Structural heart disease and/or renal disease;

          -  Dysmorphic features or congenital abnormalities;

          -  Tocolytic therapy with indomethacin or other prostaglandin inhibitor within 72 hours
             prior to delivery;

          -  Overt clinical bleeding from more than one site;

          -  Platelet count less than 50 x 109/L;

          -  Hydrops;

          -  Not considered viable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Schmidt, MD</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David K. Stevenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lu-Ann Papile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon E. Tyson, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A. Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J. Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avroy A. Fanaroff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles R. Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Oh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Womens and Infants Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatal.rti.org/</url>
    <description>NICHD Neonatal Research Network</description>
  </link>
  <link>
    <url>http://www.nichd.nih.gov/Cochrane/Fowlie/Fowlie.htm</url>
    <description>Cochrane meta-analysis: &quot;Prophylactic intravenous indomethacin in VLBW infants.&quot;</description>
  </link>
  <results_reference>
    <citation>Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001 Jun 28;344(26):1966-72.</citation>
    <PMID>11430325</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003 Mar 5;289(9):1124-9.</citation>
    <PMID>12622582</PMID>
  </results_reference>
  <results_reference>
    <citation>Ambalavanan N, Baibergenova A, Carlo WA, Saigal S, Schmidt B, Thorpe KE; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Early prediction of poor outcome in extremely low birth weight infants by classification tree analysis. J Pediatr. 2006 Apr;148(4):438-444.</citation>
    <PMID>16647401</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt B, Roberts RS, Fanaroff A, Davis P, Kirpalani HM, Nwaesei C, Vincer M; TIPP Investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr. 2006 Jun;148(6):730-734.</citation>
    <PMID>16769377</PMID>
  </results_reference>
  <results_reference>
    <citation>Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr. 2007 Jan;150(1):46-50.e2.</citation>
    <PMID>17188612</PMID>
  </results_reference>
  <results_reference>
    <citation>Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007 Mar;150(3):229-34, 234.e1.</citation>
    <PMID>17307535</PMID>
  </results_reference>
  <results_reference>
    <citation>Alfaleh K, Smyth JA, Roberts RS, Solimano A, Asztalos EV, Schmidt B; Trial of Indomethacin Prophylaxis in Preterms Investigators. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics. 2008 Feb;121(2):e233-8. doi: 10.1542/peds.2007-0028.</citation>
    <PMID>18245398</PMID>
  </results_reference>
  <results_reference>
    <citation>Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS; Trial of Indomethacin Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics. 2009 Jan;123(1):313-8. doi: 10.1542/peds.2008-0377.</citation>
    <PMID>19117897</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2001</study_first_submitted>
  <study_first_submitted_qc>February 2, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2001</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <name_title>Barbara Schmidt/ Lead Principal Investigator</name_title>
    <organization>McMaster University</organization>
  </responsible_party>
  <keyword>Chronic lung disease</keyword>
  <keyword>Indocin</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Infants, very low birth weight</keyword>
  <keyword>Intraventricular hemorrhage</keyword>
  <keyword>Necrotizing enterocolitis</keyword>
  <keyword>Patent ductus arteriosus</keyword>
  <keyword>Pulmonary hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

